The Petri Dish: bluebird gets $102M; BMS vet joins Selecta’s C-suite


Bluebird bio has sold a priority review voucher for one of its recently approved drugs for $102 million.

Previous Another biotech cuts staff as Atlas startup lays off 25%
Next South Florida multifamily investor buys Scottsdale office building where it plans its second HQ